Xiao Huang

Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research.

MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong.

MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong.

Part of Cutia Therapeutics, Cutia Therapeutics (Shanghai) Co., Ltd. develops therapeutics to treat severe facial acne vulgaris. The company is based in Shanghai, China. The Chinese company was founded in 2019. The CEO is Le Le Zhang.

Shanghai Yunfeng Investment Management Co. Ltd (Yunfeng Capital) is a private equity firm founded in 2010 by Feng Yu and Yun Ma. The firm is headquartered in Shanghai, China.

Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research.

Shanghai Yunfeng Investment Management Co. Ltd (Yunfeng Capital) is a private equity firm founded in 2010 by Feng Yu and Yun Ma. The firm is headquartered in Shanghai, China.

MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong.

MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong.

MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong.

Part of Cutia Therapeutics, Cutia Therapeutics (Shanghai) Co., Ltd. develops therapeutics to treat severe facial acne vulgaris. The company is based in Shanghai, China. The Chinese company was founded in 2019. The CEO is Le Le Zhang.

Shanghai Yunfeng Investment Management Co. Ltd (Yunfeng Capital) is a private equity firm founded in 2010 by Feng Yu and Yun Ma. The firm is headquartered in Shanghai, China.

MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong.

MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong.

Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research.

MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong.

Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research.

Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research.

MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong.

MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong.

Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research.

MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong.